Skip to main content
. 2023 Mar 8;28(8):699–705. doi: 10.1093/oncolo/oyad036

Figure 2.

Figure 2.

Patients who switched from either leuprolide or degarelix to relugolix and their therapy outcomes. One patient switched back to previous therapy due to cost and adverse effects. Abbreviation: AE, adverse effects.